

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(10) International Publication Number  
**WO 2021/161109 A1**

(43) International Publication Date  
19 August 2021 (19.08.2021)

(51) International Patent Classification:

C07F 9/40 (2006.01) C07D 471/04 (2006.01)  
C07D 265/30 (2006.01)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(21) International Application Number:

PCT/IB2021/000130

(22) International Filing Date:

12 February 2021 (12.02.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/977,004 14 February 2020 (14.02.2020) US  
63/144,902 02 February 2021 (02.02.2021) US

(71) Applicant: **BELLUS HEALTH COUGH INC.** [CA/CA];  
275 Armand-Frappier Boulevard, Laval, QC H7V 4A7  
(CA).

(72) Inventors: **CHAURET, Nathalie**; 275 Armand-Frappier  
Boulevard, Laval, QC H7V 4A7 (CA). **GREEN, Jere-**  
**my**; 275 Armand-Frappier Boulevard, Laval, QC H7V 4A7  
(CA). **KRONENTHAL, David, R.**; 275 Armand-Frappier  
Boulevard, Laval, QC H7V 4A7 (CA). **VILLENEUVE,**  
**Karine**; 275 Armand-Frappier Boulevard, Laval, QC H7V  
4A7 (CA).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,  
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,  
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,  
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,  
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a  
patent (Rule 4.17(ii))

(54) Title: PREPARATION OF A P2X3 ANTAGONIST

(57) Abstract: Described herein are two processes for the preparation of methyl (5)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidaz[1,2-a]pyridine-3-yl)methyl)morpholine-4-carboxylate, a P2X3 antagonist, in a stepwise manner and chemical intermediates used in the synthetic processes.

WO 2021/161109 A1